Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs ResMed Inc. — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.66 (market cap $31.07B), while ResMed Inc. trades at $234.01 (market cap $32.99B). The key difference: GE HealthCare Technologies Inc. Common Stock and ResMed Inc. are close in size by market cap, and ResMed Inc. pays the higher dividend (1.13%). Which is the better fit depends on your goals.
| GEHC | RMD | |
|---|---|---|
Market Cap | $31.07B | $32.99B |
Volume | 3,443,020 | 1,023,381 |
Sector | Health | Health |
52-Week High | $88.16 | $275.96 |
52-Week Low | $59.48 | $182.82 |
Enterprise Value | $39.53B | $32.35B |
Dividend Yield | 0.23% | 1.13% |
Typical Hold Time | — | 51 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
ResMed (RMD) trades at $235.29, up 0.29% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 27.2% net margins and consistent earnings beats in recent quarters. Recent news highlights include upcoming Q1 2027 earnings and management presentations at healthcare conferences, while analyst consensus remains positive with a $243.56 price target.
RMD presents a favorable investment case with strong profitability metrics and positive earnings momentum, though elevated valuation ratios and ongoing legal investigations warrant caution. The stock's technical strength supports near-term upside potential toward resistance levels, while fundamental growth drivers in sleep therapy demand provide long-term support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
